Conversion to Alzheimer's Disease Dementia from Normal Cognition Directly or with the Intermediate Mild Cognitive Impairment Stage

Overview

Journal Alzheimers Dement

Specialties Neurology
Psychiatry

Date 2024 Nov 19

PMID 39560003

Authors

Xinlin Lu

Yahui Zhang

Yichen Tang

Charles Bernick

Guogen Shan

Affiliations

Soon will be listed here.

Abstract

Introduction: Progression to Alzheimer's disease (AD) dementia from normal cognition (NC) can follow different trajectories, with most progressing through a recognizable mild cognitive impairment stage (NC-MCI-AD), while some individuals transition quickly from NC to AD dementia (NC-AD).

Methods: We compared demographic characteristics, health factors, and cognitive and functional assessments across three time points: the first NC visit, the last NC visit, and the first AD dementia visit.

Results: The NC-MCI-AD group showed greater impairment in cognitive and functional scores at AD dementia diagnosis, despite maintaining better cognitive function during the NC stage. Analysis of yearly changes revealed negligible differences during NC. However, the yearly change during the AD dementia stage suggested potentially more rapid functional decline in the NC-AD group.

Discussion: These findings highlight the heterogeneity in AD disease progression and emphasize the importance of considering diverse progression patterns in AD research and clinical practice.

Highlights: We investigated the disease progression difference between patients who converted to Alzheimer's disease (AD) dementia from normal cognition (NC) directly or through the mild cognitive impairment (MCI) stage. We found that the NC-MCI-AD group showed greater impairment in cognitive and functional scores at AD dementia diagnosis. We discovered that the NC-AD group had rapid functional decline once patients were confirmed with AD onset.

Citing Articles

Conversion to Alzheimer's disease dementia from normal cognition directly or with the intermediate mild cognitive impairment stage.

Lu X, Zhang Y, Tang Y, Bernick C, Shan G Alzheimers Dement. 2024; 21(1):e14393.

PMID: 39560003 PMC: 11772698. DOI: 10.1002/alz.14393.

References

Pfeffer R, Kurosaki T, Harrah Jr C, Chance J, Filos S . Measurement of functional activities in older adults in the community. J Gerontol. 1982; 37(3):323-9. DOI: 10.1093/geronj/37.3.323. View

Pang Y, Kukull W, Sano M, Albin R, Shen C, Zhou J . Predicting Progression from Normal to MCI and from MCI to AD Using Clinical Variables in the National Alzheimer's Coordinating Center Uniform Data Set Version 3: Application of Machine Learning Models and a Probability Calculator. J Prev Alzheimers Dis. 2023; 10(2):301-313. PMC: 10033942. DOI: 10.14283/jpad.2023.10. View

Liampas I, Siokas V, Ntanasi E, Kosmidis M, Yannakoulia M, Sakka P . Cognitive trajectories preluding the imminent onset of Alzheimer's disease dementia in individuals with normal cognition: results from the HELIAD cohort. Aging Clin Exp Res. 2022; 35(1):41-51. PMC: 9816286. DOI: 10.1007/s40520-022-02265-y. View

Shan G, Gerstenberger S . Fisher's exact approach for post hoc analysis of a chi-squared test. PLoS One. 2017; 12(12):e0188709. PMC: 5737889. DOI: 10.1371/journal.pone.0188709. View

Profenno L, Porsteinsson A, Faraone S . Meta-analysis of Alzheimer's disease risk with obesity, diabetes, and related disorders. Biol Psychiatry. 2009; 67(6):505-12. DOI: 10.1016/j.biopsych.2009.02.013. View

Scheltens P, De Strooper B, Kivipelto M, Holstege H, Chetelat G, Teunissen C . Alzheimer's disease. Lancet. 2021; 397(10284):1577-1590. PMC: 8354300. DOI: 10.1016/S0140-6736(20)32205-4. View

Alford S, Patel D, Perakakis N, Mantzoros C . Obesity as a risk factor for Alzheimer's disease: weighing the evidence. Obes Rev. 2017; 19(2):269-280. DOI: 10.1111/obr.12629. View

Masters C, Bateman R, Blennow K, Rowe C, Sperling R, Cummings J . Alzheimer's disease. Nat Rev Dis Primers. 2016; 1:15056. DOI: 10.1038/nrdp.2015.56. View

Brookmeyer R, Evans D, Hebert L, Langa K, Heeringa S, Plassman B . National estimates of the prevalence of Alzheimer's disease in the United States. Alzheimers Dement. 2011; 7(1):61-73. PMC: 3052294. DOI: 10.1016/j.jalz.2010.11.007. View

10.

Nowrangi M, Rao V, Lyketsos C . Epidemiology, assessment, and treatment of dementia. Psychiatr Clin North Am. 2011; 34(2):275-94, vii. DOI: 10.1016/j.psc.2011.02.004. View

11.

Morris J . The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993; 43(11):2412-4. DOI: 10.1212/wnl.43.11.2412-a. View

12.

Kim J, Basak J, Holtzman D . The role of apolipoprotein E in Alzheimer's disease. Neuron. 2009; 63(3):287-303. PMC: 3044446. DOI: 10.1016/j.neuron.2009.06.026. View

13.

Arevalo-Rodriguez I, Smailagic N, Roque I Figuls M, Ciapponi A, Sanchez-Perez E, Giannakou A . Mini-Mental State Examination (MMSE) for the detection of Alzheimer's disease and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev. 2015; (3):CD010783. PMC: 6464748. DOI: 10.1002/14651858.CD010783.pub2. View

14.

McGirr A, Nathan S, Ghahremani M, Gill S, Smith E, Ismail Z . Progression to Dementia or Reversion to Normal Cognition in Mild Cognitive Impairment as a Function of Late-Onset Neuropsychiatric Symptoms. Neurology. 2022; 98(21):e2132-e2139. PMC: 9169943. DOI: 10.1212/WNL.0000000000200256. View

15.

Sosa-Ortiz A, Acosta-Castillo I, Prince M . Epidemiology of dementias and Alzheimer's disease. Arch Med Res. 2012; 43(8):600-8. DOI: 10.1016/j.arcmed.2012.11.003. View

16.

Beekly D, Ramos E, Lee W, Deitrich W, Jacka M, Wu J . The National Alzheimer's Coordinating Center (NACC) database: the Uniform Data Set. Alzheimer Dis Assoc Disord. 2007; 21(3):249-58. DOI: 10.1097/WAD.0b013e318142774e. View

17.

Breijyeh Z, Karaman R . Comprehensive Review on Alzheimer's Disease: Causes and Treatment. Molecules. 2020; 25(24). PMC: 7764106. DOI: 10.3390/molecules25245789. View

18.

Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S . Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020; 396(10248):413-446. PMC: 7392084. DOI: 10.1016/S0140-6736(20)30367-6. View

19.

Bloom G . Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol. 2014; 71(4):505-8. DOI: 10.1001/jamaneurol.2013.5847. View

20.

Weintraub S, Salmon D, Mercaldo N, Ferris S, Graff-Radford N, Chui H . The Alzheimer's Disease Centers' Uniform Data Set (UDS): the neuropsychologic test battery. Alzheimer Dis Assoc Disord. 2009; 23(2):91-101. PMC: 2743984. DOI: 10.1097/WAD.0b013e318191c7dd. View